The expansion consists of an additional 89,000 sf of laboratory space equipped with state-of-the-art analytical instrumentation, high throughput bioprocessing equipment, and automation technologies. The facility is expected to double the company’s capacity to support process characterization programs complimenting enhanced capabilities at FUJIFILM Diosynth Biotechnologies’ United Kingdom facility. This expansion allows FUJIFILM Diosynth Biotechnologies to further support its partners guiding clinical process development to create more robust commercial processes.
BE&K completed the initial BioProcess Innovation Center in 2016.
As leaders in process development, we are delighted to be adding this additional capacity to support our growing pipeline of customers. The cutting-edge laboratory equipment and automation tools, combined with the deep technical expertise of our scientific community, will allow us to better serve our partners to rapidly generate and assess data to understand complex molecules, along with the processes used in their manufacture.
— Christine Vannais, Chief Operating Officer, FUJIFILM Diosynth Biotechnologies